• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Codexis Inc.

    9/26/24 9:27:32 AM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    SC 13G 1 d11483711_13-g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Codexis, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

    192005106
    (CUSIP Number)

     

     

    September 20, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    CUSIP No 192005106    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Casdin Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      8,100,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      8,100,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      8,100,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA

     
     
     

     

    CUSIP No 192005106    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners Master Fund, L.P.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      8,100,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      8,100,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      8,100,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     
     
     

     

    CUSIP No 192005106    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Casdin Partners GP, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      8,100,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      8,100,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      8,100,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     
     
     

     

    CUSIP No 192005106    

     

         
    1. NAME OF REPORTING PERSONS  
         
      Eli Casdin  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      8,100,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      8,100,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      8,100,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.9%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     
     
     

     

    CUSIP No 192005106    

     

    Item 1. (a). Name of Issuer:  
           
        Codexis, Inc.  

     

      (b). Address of Issuer's Principal Executive Offices:  
           
       

    200 Penobscot Drive

    Redwood City, CA 94063

     

     

    Item 2. (a). Name of Person Filing:  
           
       

    Casdin Capital, LLC

    Casdin Partners Master Fund, L.P.

    Casdin Partners GP, LLC

    Eli Casdin

     

     

      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Casdin Capital, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners Master Fund, L.P.

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Casdin Partners GP, LLC

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

    Eli Casdin

    1350 Avenue of the Americas, Suite 2600

    New York, New York 10019

     

     

      (c). Citizenship:  
           
       

    Casdin Capital, LLC - Delaware

    Casdin Partners Master Fund, L.P. – Cayman Islands

    Casdin Partners GP, LLC - Delaware

    Eli Casdin– United States of America

     

     

      (d). Title of Class of Securities:  
           
        Common Stock, par value $0.0001 per share  

     

      (e). CUSIP Number:  
           
        192005106  
     
     

     

    Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    8,100,000 shares deemed beneficially owned by Casdin Capital, LLC

    8,100,000 shares deemed beneficially owned by Casdin Partners Master Fund, L.P.

    8,100,000 shares deemed beneficially owned by Casdin Partners GP, LLC

    8,100,000 shares deemed beneficially owned by Eli Casdin

     

      (b)   Percent of class:
         
       

    9.9% deemed beneficially owned by Casdin Capital, LLC

    9.9% deemed beneficially owned by Casdin Partners Master Fund, L.P.

    9.9% deemed beneficially owned by Casdin Partners GP, LLC

    9.9% deemed beneficially owned by Eli Casdin

     

      (c)   Number of shares as to which Casdin Capital, LLC has:

     

      (i) Sole power to vote or to direct the vote 0  
           
      (ii) Shared power to vote or to direct the vote 8,100,000  
           
      (iii) Sole power to dispose or to direct the disposition of 0  
           
      (iv) Shared power to dispose or to direct the disposition of 8,100,000  
             
             

     

     

     
     

     

     

     

      Number of shares as to which Casdin Partners Master Fund, L.P. has:

     

      (i) Sole power to vote or to direct the vote 0  
           
      (ii) Shared power to vote or to direct the vote 8,100,000  
           
      (iii) Sole power to dispose or to direct the disposition of 0  
           
      (iv) Shared power to dispose or to direct the disposition of 8,100,000  
             

     

      Number of shares as to which Casdin Partners GP, LLC has:

     

      (i) Sole power to vote or to direct the vote 0  
           
      (ii) Shared power to vote or to direct the vote 8,100,000  
           
      (iii) Sole power to dispose or to direct the disposition of 0  
           
      (iv) Shared power to dispose or to direct the disposition of 8,100,000  
             

     

      Number of shares as to which Eli Casdin has:

     

      (i) Sole power to vote or to direct the vote 0  
           
      (ii) Shared power to vote or to direct the vote 8,100,000  
           
      (iii) Sole power to dispose or to direct the disposition of 0  
           
      (iv) Shared power to dispose or to direct the disposition of 8,100,000  
             

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].
       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
       
     
     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       
       

     

     

     
     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

        September 26, 2024  
        (Date)  

     

     

    Casdin Capital, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.*

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC*

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin*
      Eli Casdin

     

     

     

     

    * The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

     

    Exhibit A

    AGREEMENT

    The undersigned agree that this Schedule 13G dated September 26, 2024 relating to the Common Stock, par value $0.0001 per share of Codexis, Inc., shall be filed on behalf of the undersigned.

     

    Casdin Capital, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners Master Fund, L.P.

    By: Casdin Partners GP, LLC, its general partner

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)

     

     

    Casdin Partners GP, LLC

     

    By: /s/ Eli Casdin

      (Signature)
       
      Eli Casdin, Managing Member
      (Name/Title)
       
       
      /s/ Eli Casdin
      Eli Casdin

     

     

     

     

    Get the next $CDXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $104,096 worth of shares (45,000 units at $2.31) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/2/25 4:05:14 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $55,915 worth of shares (25,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/29/25 4:05:11 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $298,772 worth of shares (140,000 units at $2.13) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/17/25 6:07:35 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Codexis downgraded by The Benchmark Company

      The Benchmark Company downgraded Codexis from Buy to Hold

      8/19/24 8:50:44 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Jefferies resumed coverage on Codexis with a new price target

      Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

      6/3/24 8:45:11 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Cantor Fitzgerald initiated coverage on Codexis with a new price target

      Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

      5/30/24 7:33:26 AM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Codexis Inc.

      SC 13G - CODEXIS, INC. (0001200375) (Subject)

      9/26/24 9:27:32 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Codexis Inc.

      SC 13G/A - CODEXIS, INC. (0001200375) (Subject)

      9/18/24 4:50:02 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by Codexis Inc.

      SC 13G - CODEXIS, INC. (0001200375) (Subject)

      7/12/24 4:15:13 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Financials

    Live finance-specific insights

    See more

    $CDXS
    Leadership Updates

    Live Leadership Updates

    See more

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CDXS
    SEC Filings

    See more
    • Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

      Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil

      5/7/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis to Report First Quarter 2025 Financial Results on May 14

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter

      4/30/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

      Total revenue of $59.3 million for the fiscal year ended December 31, 2024 Expect double digit growth for total revenue in 2025 2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. "Throughout 2024, we continued to execute our strategy to advance the ECO Synthesis™ platform, a

      2/27/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Appoints Cynthia Collins to Board of Directors

      REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

      4/1/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

      REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact

      2/6/25 4:05:30 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Appoints Christos Richards to Board of Directors

      REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies

      1/16/25 4:05:27 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

      Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis double-stranded RNA ligases Management will host a conference call at 8 am Eastern Time on Thursday, May 22 to discuss data REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will host two data presentations and one poster at the upcoming TIDES USA annual meeting, being held May 19-22, 2025, in San Diego, California. Codexis' presentations wil

      5/7/25 7:00:00 AM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis to Report First Quarter 2025 Financial Results on May 14

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (inter

      4/30/25 4:05:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Announces Byron Dorgan to Retire from Board of Directors

      REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board. "On behalf of the entire Board of Directors, I want to express our appreciation for Byron's valuabl

      4/9/25 5:00:00 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form DEFA14A filed by Codexis Inc.

      DEFA14A - CODEXIS, INC. (0001200375) (Filer)

      4/24/25 4:05:44 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • SEC Form DEF 14A filed by Codexis Inc.

      DEF 14A - CODEXIS, INC. (0001200375) (Filer)

      4/24/25 4:05:28 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Codexis Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - CODEXIS, INC. (0001200375) (Filer)

      4/9/25 5:07:32 PM ET
      $CDXS
      Major Chemicals
      Industrials

    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Opaleye Management Inc. bought $104,096 worth of shares (45,000 units at $2.31) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      5/2/25 4:05:14 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $55,915 worth of shares (25,000 units at $2.24) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/29/25 4:05:11 PM ET
      $CDXS
      Major Chemicals
      Industrials
    • Large owner Opaleye Management Inc. bought $298,772 worth of shares (140,000 units at $2.13) (SEC Form 4)

      4 - CODEXIS, INC. (0001200375) (Issuer)

      4/17/25 6:07:35 PM ET
      $CDXS
      Major Chemicals
      Industrials